Volatile Week, but Green? Click to watch the new Podcast.

Esperion Therapeutics Stock Forecast

NASDAQ:ESPR BUY SELL

$6.99 (8.37%)

Volume: 1.04M

Closed: Jul 05, 2022

Hollow Logo Score: 6.620

Esperion Therapeutics Stock Forecast

BUY SELL NASDAQ:ESPR
$6.99 (8.37%)

Volume: 1.04M

Closed: Jul 05, 2022

Score Hollow Logo 6.620

ESPR Price Targets and Analyst Ratings NASDAQ:ESPR

Historical Ratings and Targets

Date Upside / Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
2022-05-24 -57.08% Goldman Sachs $3.50 $3.00 Maintains Sell
2022-05-05 - JP Morgan - Upgrades Underweight Neutral
2022-03-10 214.74% HC Wainwright & Co. $22.00 Initiates Coverage On Buy
2022-01-14 -14.16% Credit Suisse $8.00 $6.00 Maintains Neutral
2021-12-09 71.67% Needham $20.00 $12.00 Maintains Buy
2021-12-06 14.45% Credit Suisse $11.00 $8.00 Maintains Neutral
2021-12-06 -28.47% Goldman Sachs $8.00 $5.00 Maintains Sell
2021-10-19 57.37% Credit Suisse $28.00 $11.00 Downgrades Outperform Neutral
2021-10-14 57.37% Morgan Stanley $11.00 Downgrades Equal-Weight Underweight
2021-08-04 143.2% Morgan Stanley $22.00 $17.00 Maintains Equal-Weight
2021-08-03 1530.9% Needham $134.00 $114.00 Maintains Strong Buy
2021-05-05 415.02% Credit Suisse $45.00 $36.00 Maintains Outperform
2021-05-05 186.12% Stifel $37.00 $20.00 Downgrades Buy Hold
2021-05-05 1487.98% JMP Securities $191.00 $111.00 Maintains Market Outperform
2021-05-05 243.35% Northland Capital Markets $30.00 $24.00 Maintains Market Perform
2021-05-05 214.74% Morgan Stanley $30.00 $22.00 Maintains Equal-Weight
2021-03-11 329.18% Morgan Stanley $30.00 Initiates Coverage On Equal-Weight
2021-02-24 1817.02% Needham $150.00 $134.00 Maintains Strong Buy
2021-02-12 329.18% Jefferies $40.00 $30.00 Downgrades Buy Hold
2021-02-09 243.35% Goldman Sachs $24.00 Downgrades Neutral Sell
2021-01-15 400.72% B of A Securities $35.00 Downgrades Buy Neutral
2020-11-10 - Credit Suisse - Upgrades Neutral Outperform
2020-10-15 643.92% B of A Securities $55.00 $52.00 Maintains Buy
2020-08-17 686.84% B of A Securities $60.00 $55.00 Maintains Buy
2020-08-11 543.78% Credit Suisse $83.00 $45.00 Downgrades Outperform Neutral
2020-05-07 901.43% Jefferies $85.00 $70.00 Maintains Buy
2020-04-16 500.86% Northland Capital Markets $60.00 $42.00 Maintains Market Perform
2020-04-01 615.31% B of A Securities $50.00 Initiates Coverage On Buy
2020-03-17 - Citigroup - Upgrades Neutral Buy
2020-02-28 572.39% JP Morgan $46.00 $47.00 Maintains Neutral
2020-02-24 2160.37% Needham $144.00 $158.00 Maintains Strong Buy
2020-02-24 - Northland Capital Markets - Downgrades Outperform Market Perform
2020-02-14 1073.1% Citigroup $73.00 $82.00 Downgrades Buy Neutral
2019-09-18 901.43% Stifel $112.00 $70.00 Maintains Buy
2019-09-16 543.78% Goldman Sachs $55.00 $45.00 Upgrades Sell Neutral
2019-05-29 615.31% Goldman Sachs $50.00 Downgrades Neutral Sell

ESPR Stock Trend

The stock lies in the upper part of a very wide and strong rising trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break-up at the top trend line at $7.09 will firstly indicate a stronger rate of rising.

Given the current short-term trend, the stock is expected to rise 12.69% during the next 3 months and, with a 90% probability hold a price between $5.71 and $7.99 at the end of this 3-month period.

Data

Date Bottom Mid Top
2022-07-07 $5.08 $6.09 $7.10
2022-07-08 $5.09 $6.10 $7.12
2022-07-11 $5.11 $6.12 $7.13
2022-07-12 $5.12 $6.13 $7.14
2022-07-13 $5.13 $6.14 $7.16
2022-07-14 $5.15 $6.16 $7.17
2022-07-15 $5.16 $6.17 $7.18
2022-07-18 $5.17 $6.18 $7.20
2022-07-19 $5.19 $6.20 $7.21
2022-07-20 $5.20 $6.21 $7.22
2022-07-21 $5.21 $6.22 $7.24
2022-07-22 $5.23 $6.24 $7.25
2022-07-25 $5.24 $6.25 $7.26
2022-07-26 $5.25 $6.26 $7.28
2022-07-27 $5.27 $6.28 $7.29
2022-07-28 $5.28 $6.29 $7.30
2022-07-29 $5.29 $6.30 $7.32
2022-08-01 $5.31 $6.32 $7.33
2022-08-02 $5.32 $6.33 $7.34
2022-08-03 $5.33 $6.34 $7.35
2022-08-04 $5.35 $6.36 $7.37
2022-08-05 $5.36 $6.37 $7.38
2022-08-08 $5.37 $6.38 $7.39
2022-08-09 $5.39 $6.40 $7.41
2022-08-10 $5.40 $6.41 $7.42
2022-08-11 $5.41 $6.42 $7.43
2022-08-12 $5.43 $6.44 $7.45
2022-08-15 $5.44 $6.45 $7.46
2022-08-16 $5.45 $6.46 $7.47
2022-08-17 $5.47 $6.48 $7.49

IMPROVE YOUR TRADING GAME WITH A GOLDEN STAR

From 26 360 stocks, only a few dozen will trigger such a signal!

About Esperion Therapeutics

Esperion Therapeutics Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. Its lead product candidate is ETC-1002 or Bempedoic acid, an inhibitor of ATP Citrate Lyase, an enzyme on the cholesterol biosynthesis pathway that is in Phase III long-term safety and tolerability study to... Read more

.

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT